James B. Bingham, Ph.D. | Chief Development Officer
|Dr. Bingham has a broad range of experience in the biopharmaceutical industry including: the fields of process development; process validation; formulation & stability; protein conjugation; fill/finish; analytical method development, qualification, and validation; drug delivery technology; quality control; quality assurance; manufacturing; CMC regulatory affairs; and facilities engineering. Dr. Bingham advanced from Director of Development to Senior Vice President of Development, Manufacturing and Quality at Amplimmune (now MedImmune/AstraZeneca). From his time as Associate Director of Microbial R & D at Lonza and Cambrex, he brings experience in financial management, organizational & resource management, corporate integration, customer relations, and technical support of Sales and Marketing. Prior to joining Lonza, Dr. Bingham managed teams in process development, formulation, analytical, drug delivery, and in-process technologies groups with Human Genome Sciences (now GlaxoSmithKline) in Rockville, Maryland. Prior to his tenure at HGS, Dr. Bingham was also employed at MedImmune and Integrated Genetics (now Sanofi Genzyme). Dr. Bingham received his Ph.D. in Biological Chemistry from The Johns Hopkins University and completed a concurrent fellowship at The Marine Biological Labs, Woods Hole, Massachusetts. His Bachelor of Science in Biology with a strong focus in Organic Chemistry and Protein Chemistry was earned at St. Michael’s College.||• Michael Richman
President & CEO
• Steven P. Cobourn, CPA
• Kevin N. Heller, M.D.
• James B. Bingham, Ph.D.
• Sol Langermann, Ph.D.
• Linda Liu, Ph.D.
Senior Vice President, Research
• Timothy Mayer, Ph.D.
Senior Vice President, Corporate Development
• Sebastien Maloveste, Ph.D.
Vice President, Business Development
• Dallas Flies, Ph.D.
Vice President, Discovery Research